The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate

Elie A. Benaim; Jose A. Karam; M. Hossein Soboorian; Claus Roehrborn; John D. McConnell; Victor Lin

doi:10.1002/pros.20070

The effect of combined androgen ablation on the expression of alpha _1A-adrenergic receptor in the human prostate

Elie A. Benaim, Jose A. Karam, M. Hossein Soboorian, Claus Roehrborn, John D. McConnell, Victor Lin

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha_1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha_1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha_1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha_1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha_1A-AR mRNA expression in the human prostate.

Original language	English (US)
Pages (from-to)	310-316
Number of pages	7
Journal	Prostate
Volume	60
Issue number	4
DOIs	https://doi.org/10.1002/pros.20070
State	Published - Sep 1 2004

Keywords

Alpha blocker therapy
Androgen ablation
BPH
MRNA expression
RT-PCR

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1002/pros.20070

Cite this

@article{a4310c3348294f0f9931eb7f9e07eb4a,

title = "The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate",

abstract = "BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.",

keywords = "Alpha blocker therapy, Androgen ablation, BPH, MRNA expression, RT-PCR",

author = "Benaim, {Elie A.} and Karam, {Jose A.} and Soboorian, {M. Hossein} and Claus Roehrborn and McConnell, {John D.} and Victor Lin",

year = "2004",

month = sep,

day = "1",

doi = "10.1002/pros.20070",

language = "English (US)",

volume = "60",

pages = "310--316",

journal = "Prostate",

issn = "0270-4137",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - The effect of combined androgen ablation on the expression of alpha 1A-adrenergic receptor in the human prostate

AU - Benaim, Elie A.

AU - Karam, Jose A.

AU - Soboorian, M. Hossein

AU - Roehrborn, Claus

AU - McConnell, John D.

AU - Lin, Victor

PY - 2004/9/1

Y1 - 2004/9/1

N2 - BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.

AB - BACKGROUND. This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate. METHODS. Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH. RESULTS. Mean concentration of alpha1A-AR in the AA group was 0.53 ± 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 ± 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content. CONCLUSIONS. A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.

KW - Alpha blocker therapy

KW - Androgen ablation

KW - BPH

KW - MRNA expression

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=3943084846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3943084846&partnerID=8YFLogxK

U2 - 10.1002/pros.20070

DO - 10.1002/pros.20070

M3 - Article

C2 - 15264242

AN - SCOPUS:3943084846

SN - 0270-4137

VL - 60

SP - 310

EP - 316

JO - Prostate

JF - Prostate

IS - 4

ER -